The global Induced Pluripotent Stem Cells Market size is expected to reach USD 3.09 billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.
Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.
Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.
The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.
Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.
List of Key Players in the Induced Pluripotent Stem Cells Market
- STEMCELL Technologies Inc.
- Cellular Engineering Technologies Inc.
- REPROCELL Inc.
- Takara Bio, Inc.
- Axol Bioscience Ltd.
- Fate Therapeutics, Inc.
- FUJIFILM Cellular Dynamics, Inc.
- Cynata Therapeutics Limited
- Evotec SE
- Astellas Pharma Inc.
Related Press Release@ Induced Pluripotent Stem Cells Market Report
Induced Pluripotent Stem Cells Market Report highlights
- By derived cell type, the fibroblasts segment accounted for the largest share of 30.48% in 2022. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
- By application, the drug developmentsegment accounted for the largest share of 49.09% in 2022. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
- By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.77% in 2022. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
- North America held the larger share of 42.36% in 2022. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.
Induced Pluripotent Stem Cells Market Report Scope
Report Attribute
Details
Market size value in 2023
USD 1.52 billion
Revenue forecast in 2030
USD 3.09 billion
Growth rate
CAGR of 10.61% from 2023 to 2030
Base year for estimation
2022
Historical data
2018 - 2021
Forecast period
2023 - 2030
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/455568/rfc
Induced Pluripotent Stem Cells Market Segmentation
Grand view research has segmented the global induced pluripotent stem cells market based on derived cell type, application, end-user, and region:
Induced Pluripotent Stem Cells Derived Cell Type Outlook (Revenue, USD Million, 2018 - 2030)
- Hepatocytes
- Fibroblasts
- Keratinocytes
- Amniotic Cells
- Others
Induced Pluripotent Stem Cells Application Outlook (Revenue, USD Million, 2018 - 2030)
- Drug Development
- Tissue Engineering & Regenerative Medicine
- Neurology
- Orthopedics
- Oncology
- Cardiovascular and Myocardial Infraction
- Diabetes
- Others
- Toxicology Research
- Disease Modeling
Induced Pluripotent Stem Cells End-user Outlook (Revenue, USD Million, 2018 - 2030)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Induced Pluripotent Stem Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Induced Pluripotent Stem Cell (IPSC) Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the induced pluripotent stem cell (IPSC) industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected induced pluripotent stem cell (IPSC) market growth numbers 2021-2030.View Complete Report:https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-marketThe Induced Pluripotent Stem Cell (IPSC) Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global induced pluripotent stem cell (IPSC) market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Induced Pluripotent Stem Cell (IPSC) Global Market Report 2021 covers induced pluripotent stem cell (IPSC) market drivers, induced pluripotent stem cell (IPSC) market trends, induced pluripotent stem cell (IPSC) market growth rate, induced pluripotent stem cell (IPSC) market major players, player-adopted strategies in the market, and induced pluripotent stem cell (IPSC) market size.The global induced pluripotent stem cell market reached a value of nearly $2,223.5 million in 2020, having increased at a compound annual growth rate (CAGR) of 9.2% since 2015.
The market is expected to grow from $2,223.5 million in 2020 to $3,362.1 million in 2025 at a rate of 8.6%.
The IPSC market is then expected to grow at a CAGR of 6.2% from 2025 and reach $4,547.7 million in 2030.
Global Induced Pluripotent Stem Cells Market ReportThe ‘Global Induced Pluripotent Stem Cells Market Insights, Forecast to 2027’ offers a comprehensive evaluation of the Induced Pluripotent Stem Cells market on the global scale and sheds light on the growth opportunities and prospects to help readers formulate strategic plans.
The report also offers relevant and useful information to help the new entrants and established companies strengthen their market position and formulate strategic approaches to gain a robust footing in the market.
The report also provides insightful data about market capacities, technological advancements, R developments, and other key features.The report is furnished with the latest market scenario and financial condition pertaining to the after-effects of the COVID-19 pandemic.
The report assesses the impact of the COVID-19 pandemic on the Induced Pluripotent Stem Cells market and key segments.
The report also studies the impact of the COVID-19 pandemic on the global supply chains and economic scenario of the industry.
It considers the COVID-19 pandemic as a key factor influencing the growth of the Induced Pluripotent Stem Cells market.Pre Book the report @ https://www.reportsanddata.com/checkout-form/3551Key Manufacturers in the Global Induced Pluripotent Stem Cells Market:Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc.The report offers an in-depth analysis of the value chain, upstream and downstream factors, sales network and distribution channels, growth trends, driving and restraining factors, developments, production and consumption pattern, end-users, and regional bifurcation.
A dramatic ascent in a mesenchymal foundational microorganism (MSC) based examination and its suggestions in the field of regenerative medication fuel the development of the market.
The continually developing scene of undifferentiated organism treatments is additionally expected to impel interests in the MSC market space; huge scope operational elements are focusing on little or arising players with a working system of securing to help their market presence.
The strong pipeline of mesenchymal youthful microorganism-based things joined with emerging uses of mesenchymal lacking cells is required to accelerate the mesenchymal stem cells market improvement.
Likewise, a significant number of associations are examining the capacity of MSCs as therapeutics zeroed in on the treatment of searing issues, along these lines boosting the market improvement.
For instance, Takeda/TiGenix stage 3 clinical fundamental breakers MSCs for complex perianal fistulas in Crohn's Disease.
This is the best late-stage clinical primer as of September 2020.
